Holen Sie sich die Stockscreener-App
26.76
7.25%
-2.08
Schlusskurs vom Vortag:
$28.84
Offen:
$29.68
24-Stunden-Volumen:
270.01K
Relative Volume:
3.36
Marktkapitalisierung:
$1.20B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-4.84%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$26.32
$29.80
1-Wochen-Bereich:
$26.01
$29.80
52-Wochen-Spanne:
$25.05
$32.23
Avalyn Pharma Inc Stock (AVLN) Company Profile
Firmenname
Avalyn Pharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare AVLN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
27.00 | 1.28B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
436.53 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.05 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.75 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.32 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.77 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalyn Pharma Inc Aktie (AVLN) Neueste Nachrichten
This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Evercore Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $51 - Moomoo
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Jefferies Initiates Avalyn Pharma at Buy With $52 Price Target - Moomoo
Morgan Stanley Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $53 - Moomoo
Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating - Investing.com Australia
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs By Investing.com - Investing.com Australia
Jefferies initiates Avalyn Pharma stock with buy on lung disease data - Investing.com
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs - Investing.com Australia
Jefferies Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $52 - Moomoo
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
AVLN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AVLN Technical Analysis | Trend, Signals & Chart Patterns | AVALYN PHARMA INC (NASDAQ:AVLN) - ChartMill
Avalyn Pharma to present 4-year AP01 data at EULAR conference By Investing.com - Investing.com South Africa
Avalyn Pharma to present 4-year AP01 data at EULAR conference - Investing.com
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 - The Manila Times
4 years on inhaled pirfenidone for lung scarring at EULAR 2026 - Stock Titan
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
AVLN SEC FilingsAVALYN PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
AVLN News | AVALYN PHARMA INC (NASDAQ:AVLN) - ChartMill
Number of shareholders of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Avalyn Pharma prices $300M IPO at $18 per share - MSN
Suvretta funds build Avalyn Pharma (AVLN) stake via IPO and open-market buys - Stock Titan
SR One funds disclose 3.31M-share Avalyn Pharma (AVLN) position after IPO - Stock Titan
What is the current Price Target and Forecast for Avalyn Pharma Inc. (AVLN) - Zacks Investment Research
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga
Perceptive group discloses 6.0% stake in Avalyn Pharma (NASDAQ: AVLN) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Avalyn brings patient feedback on lung fibrosis care to ATS 2026 - Stock Titan
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference - The Manila Times
Lung disease drug developer Avalyn surges on public debut - MSN
Novo Holdings (NASDAQ: AVLN) buys shares and converts preferred into Avalyn common - Stock Titan
Avalyn Pharma Insider Bought Shares Worth $5,000,004, According to a Recent SEC Filing - Moomoo
Avalyn Pharma Inc. (AVLN) - Minichart
Preferred dividends of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
After tax other income/expense of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Cash per share of Avalyn Pharma Inc. – BOATS:AVLN - TradingView
Number of employees of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
AVLN PE Ratio & Valuation, Is AVLN Overvalued - Intellectia AI
Avalyn Pharma completes $345 million IPO on nasdaq - Investing.com India
AVLN Price Today: Avalyn Pharma Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Avalyn Pharma completes $345 million IPO on nasdaq By Investing.com - Investing.com Canada
Avalyn Pharma (AVLN) 10K Form and Latest SEC Filings 2026 - MarketBeat
IPO NewsUS IPO Weekly Recap: Biotech, early-stage mining, and Bill Ackman close out the April IPO market - renaissancecapital.com
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs - Citeline News & Insights
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Avalyn Pharma closes $345 million IPO on Nasdaq By Investing.com - Investing.com Australia
Avalyn Pharma Inc. Completes Successful Initial Public Offering Raising $345 Million - Moomoo
Finanzdaten der Avalyn Pharma Inc-Aktie (AVLN)
Es liegen keine Finanzdaten für Avalyn Pharma Inc (AVLN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Avalyn Pharma Inc-Aktie (AVLN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Carroll Jill | Director |
May 01 '26 |
Buy |
18.00 |
277,778 |
5,000,004 |
2,186,562 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 01 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
2,186,562 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):